A Phase 3 interventional study of DIAB-PHC1 and Metformin in Diabetes Type 2, Diabetes Mellitus, Experimental and HbA1c, sponsored by Hamdard University. Active, not recruiting at 1 site in Pakistan. Open to participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2025-12-12.
Sponsored by Hamdard University · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in Diabetes Mellitus, Type 2 with a site in Pakistan — 28 open to participants now, 35 under way, 2 of them phase 3. Diabetes Mellitus, Type 2 · Pakistan.
Among the 98 studies in Diabetes Mellitus, Type 2 with a site in Pakistan, this one is the 9th largest by enrollment of the 89 interventional ones that give a count, is one of 14 that started in 2024, is one of 2 in phase 3, reaches primary completion later than 9 of the 34 other live ones, and was the 76th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →28 of the 98 studies in Diabetes Mellitus, Type 2 with a site in Pakistan are open now. Recruiting first, the newest first:
Riphah International University · Sites in Pakistan
Ages 40–65
Green International University · Sites in Pakistan
Ages 30–65
Ibadat International University, Islamabad · Sites in Pakistan
Ages 50–70
Foundation University Islamabad · Sites in Pakistan
Ages 30–55
Khyber Medical University Peshawar · Sites in Pakistan
Ages 20+ · Healthy volunteers
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 30 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 5 · Phase 3 3 · Phase 4 21
First in 2006; this study’s year is marked. 14 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 500 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 99 across the 89 interventional studies, 1,031 across the 9 observational. Of the 56 that completed or were terminated, 5 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 98 have an industry lead sponsor. The 10 most frequent:
Hamdard University is the lead sponsor of 19 studies on the registry; 5 are open to participants now.
Hamdard University has 2 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
12 of the studies in Diabetes Mellitus, Type 2 with a site in Pakistan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073768Phase 3Khyber Medical College, PeshawarComparison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabetic Patients | 2026-12-26 |
| NCT06570057Baqai Institute of Diabetology and EndocrinologyFeasibility Trial in Urban Pakistan for Community Engagement in Preventing Type II Diabetes and Risk Factors | 2026-11 |
| NCT06561126Khyber Medical University PeshawarEngagement of coMmunity Through Participatory Learning and Action for cOntrol and preVEntion of Type II Diabetes and Its Risk Factors [EMPOWER-D] | 2026-11-30 |
| NCT07814742National University of Medical Sciences, PakistanEffectiveness of UrDiaCare | 2026-12-31 |
| NCT05164263Getz PharmaReal World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study | 2026-12-31 |
Add all 12 to your calendar (.ics) → With an account.
Among the 98 studies in Diabetes Mellitus, Type 2 with a site in Pakistan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial to learn the clinical efficacy and safety of standardized polyherbal capsule weighing around 500 mg, containing Syzygium cumini, Momordica charantia, Wrightia tinctoria, and Gymnema sylvestre in equal proportions for controlling Diabetic hyperglycemia towards a normal glycemic control. The main question that aims to search is
Does this treatment plan reduces the blood sugar level comparative to Metformin 500 mg TID The trial is also comparing its efficacy in comparison to a standard anti diabetic drug Metformin In the study wing, the volunteer diabetic patients will take the herbal capsule 500mg TID and in the control group the volunteer patients will take Metformin 500 mg TID.
Preclinical evaluation studies including stability, dissolution and anti-microbial testing were performed. The formulation was also subjected to gas chromatography-mass spectrometry (GCMS). The powdered formulation was analyzed for LD-50 followed by two-center, unblinded, non-randomized controlled clinical trial with convenient sampling was conducted over 24 weeks in 500 adults with T2DM (HbA1c 7.5-10%). Participants were assigned to receive either polyherbal capsules (\~500 mg three times daily, n = 250) or metformin (500 mg three times daily, n = 250). Primary outcome was HbA1c reduction; secondary outcomes included fasting/postprandial glucose, urinary protein, urinary glucose, lipid profile, body weight, and safety. Statistical analyses were performed using two-way ANOVA and unpaired t-tests.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who do not agree willingly to participate in research.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metformin is standardized hypoglycemic agent with global accepted efficacy \& safety
Drug: Metformin
The investigational formulation consisted of Syzygium cumini, Momordica charantia, Wrightia tinctoria and Gymnema sylvestre. Raw plant materials were procured from local herbal markets and authenticated shade dried and powdered. The powder was capsulated with avverage weight of 500 mg /capsule. Capsules were given TID with meals to the patients
Drug: DIAB-PHC1
a novel poly-herbal hard gelatin capsule formulation comprising Syzygium cumini, Momordica charantia, Wrightia tinctoria, and Gymnema sylvestre in a scientifically optimized ratio. Although each of these herbs is traditionally recognized for its individual anti-diabetic activity, their combination in a standardized dosage form has not previously been reported. The study further strengthens its novelty by conducting comprehensive pre-clinical safety evaluations, confirming the absence of toxicity before proceeding to controlled clinical investigations.
Standard oral hypoglycemic comparator
Also known as: Glucophage
glycated hemoglobin (HbA1c)
The primary objective is to assess improvements in glycated hemoglobin (HbA1c) and fasting/ post-prandial plasma glucose.
Time frame: From two weeks to six months time period
Urinary Proteins
The secondary objectives are to evaluate reduction in the amount of proteins in urine
Time frame: At least Six months
Urinary Glucose
regular check for the urinary glucose levels as a parameter for improved glycemic control
Time frame: 6 months
Plan to share: No — to keep the privacy \& anonymity of the individual participant of the study, as committed at the time of induction
Ran from Mar 2024 to primary completion in Aug 2025, 16 months.
Of 87 non-industry phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 16 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hamdard University